Same molecule, same injection, same side effects. Different indication, different dose, different insurance coverage. That is basically the whole story.
🔑 Key Takeaways
- Wegovy and Ozempic contain the exact same active ingredient (semaglutide) from the same manufacturer (Novo Nordisk). The difference is indication, dose, and pen design
- Wegovy is FDA-approved for chronic weight management in adults with BMI 30+, or 27+ with comorbidity, and adolescents 12+ with obesity. It is also approved for cardiovascular risk reduction in obesity and for MASH (liver disease)
- Ozempic is FDA-approved for type 2 diabetes, cardiovascular risk reduction in T2D with heart disease, and kidney disease protection in T2D with chronic kidney disease. Weight loss is a side effect, not an indication
- Wegovy reaches a higher maximum dose (2.4 mg weekly) compared to Ozempic (2.0 mg weekly), which produces more weight loss
- Ozempic uses multi-dose pens with 4 to 8 doses per pen. Wegovy uses single-dose pens with one dose per pen
- Side effect profiles are essentially identical (nausea, diarrhea, constipation, vomiting, thyroid boxed warning). Rates are slightly higher on Wegovy because the dose is higher
- Insurance usually covers Ozempic easily with a T2D diagnosis. Wegovy coverage requires obesity-specific prior authorization and is harder to get approved
- Off-label Ozempic for weight loss is common, but is less effective than Wegovy because of the lower max dose
This page answers every common question about the Wegovy vs Ozempic decision: the FDA approvals that differentiate them, why the maximum doses differ, what the trials actually showed, side effect and cost comparison, insurance realities, who should pick which, and whether you can switch between them.
What's the Difference Between Wegovy and Ozempic?
Same molecule. Different target patient.
Both contain semaglutide, a GLP-1 receptor agonist from Novo Nordisk. The chemistry is identical. What differs is what the FDA approved each brand for, the dose range, and the pen design. Wegovy was designed for weight management and reaches a higher therapeutic dose. Ozempic was designed for type 2 diabetes and tops out at a slightly lower dose. Neither is interchangeable with the other, even though they work through exactly the same mechanism in the body.
Wegovy vs Ozempic: Specs Side-by-Side
| Wegovy | Ozempic | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA indication | Chronic weight management, CV risk reduction in obesity, MASH | Type 2 diabetes, CV risk reduction in T2D, kidney disease protection in T2D |
| Approved ages | Adults, adolescents 12+ | Adults (not approved for adolescents) |
| Max weekly dose | 2.4 mg | 2.0 mg |
| Starting dose | 0.25 mg weekly | 0.25 mg weekly |
| Pen design | Single-dose pen (one per injection) | Multi-dose pen (4 to 8 doses per pen) |
| Injection frequency | Once weekly | Once weekly |
| Avg weight loss | ~14.9% (STEP 1 at 68 weeks) | ~5-10% (off-label, at lower max dose) |
| List price / month | ~$1,350 | ~$900 |
| Cash program | NovoCare $199 (months 1-2), $349 after | No dedicated cash program (insurance-based) |
FDA-Approved Uses: Where They Differ
The single biggest practical difference.
Wegovy approvals
- Chronic weight management: Adults with BMI 30+, or 27+ with a weight-related condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea)
- Pediatric obesity: Adolescents age 12+ with BMI in the 95th percentile or higher
- Cardiovascular risk reduction: Adults with obesity and established cardiovascular disease, based on the SELECT trial (20% reduction in major CV events)
- MASH (metabolic dysfunction-associated steatohepatitis): Added indication for adults with moderate to advanced liver fibrosis
Ozempic approvals
- Type 2 diabetes: Primary indication, as an adjunct to diet and exercise for glycemic control
- Cardiovascular risk reduction in T2D: For adults with T2D and established cardiovascular disease
- Kidney disease protection: For adults with T2D and chronic kidney disease
Ozempic is widely prescribed off-label for weight loss in people who do not have T2D. This is legal but produces less weight loss than Wegovy because the max dose is lower, and insurance often denies the prescription without a T2D diagnosis.
Wegovy vs Ozempic for Weight Loss
Both work. Wegovy works more.
The STEP 1 trial (NEJM 2021) established Wegovy's weight loss efficacy: 14.9% average body weight reduction at 68 weeks on 2.4 mg weekly, with 86% of participants achieving at least 5% weight loss and 50% achieving 15% or more.
Ozempic at its max 2.0 mg weekly dose produces roughly 5 to 10% average weight loss in off-label weight-management use. At the diabetes doses (0.5 to 1.0 mg), weight loss is smaller. The dose ceiling is the main reason Wegovy outperforms Ozempic for weight management.
No large head-to-head trial has directly compared Wegovy vs Ozempic at each drug's maximum dose specifically for weight loss. The comparison rests on cross-trial data and the shared pharmacology: same molecule, higher dose produces proportionally more effect.
Dosing and Titration
Both drugs titrate slowly from the same starting dose to reduce GI side effects.
Wegovy Titration (for weight management)
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1.0 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (target maintenance dose)
Ozempic Titration (for type 2 diabetes)
- Weeks 1-4: 0.25 mg weekly (starting, not yet therapeutic)
- Weeks 5-8: 0.5 mg weekly
- If needed: Increase to 1.0 mg weekly
- Max: 2.0 mg weekly (added in 2022 for additional glycemic control)
Holding a dose level for an extra 4 weeks when GI symptoms are strong is acceptable for both drugs. Every step-up triggers a new wave of nausea for many patients, which usually fades within 2 to 4 weeks at the new dose.
Wegovy vs Ozempic Side Effects
Same profile, slightly different rates.
Because Wegovy is dosed higher, side effects are more common on Wegovy than on Ozempic. The side effect categories are identical.
| Side effect | Wegovy 2.4 mg | Ozempic 1.0 mg |
|---|---|---|
| Nausea | ~44% | ~20% |
| Diarrhea | ~30% | ~12% |
| Vomiting | ~24% | ~9% |
| Constipation | ~24% | ~5% |
| Headache | ~14% | ~7% |
| Fatigue | ~11% | ~4% |
Both carry the identical boxed warning for medullary thyroid carcinoma and MEN2 family history. Both carry the same rare-but-serious risks: pancreatitis, gallbladder disease, kidney injury, hypersensitivity reactions, and diabetic retinopathy worsening in patients with pre-existing retinopathy.
Cost: Wegovy vs Ozempic
| Option | Wegovy | Ozempic |
|---|---|---|
| List price (cash) | ~$1,350/month | ~$900/month |
| Manufacturer cash program | NovoCare: $199 months 1-2, $349 after | No dedicated cash program |
| Commercial insurance | $25-$250 copay (with PA) | $25-$200 copay (usually easier to get approved) |
| Medicare | Covered under GLP-1 Bridge Program starting July 1, 2026 (~$50/month) | Covered for T2D only |
| Medicaid | Varies by state | Usually covered for T2D |
NovoCare is the most meaningful 2026 cost change. For uninsured or underinsured patients, $199/month for the first 2 months and $349/month after is significantly better than the $1,350 list price. See our GLP-1 without insurance page for the full options.
Insurance Reality
The practical difference patients actually feel.
Ozempic is usually approved by commercial insurance with a type 2 diabetes diagnosis, a standard prior authorization, and minimal friction. Medicare Part D covers it for T2D. Medicaid covers it in most states for T2D.
Wegovy is harder. Commercial insurers require obesity-specific prior authorization, usually with documented BMI, at least one comorbidity, evidence of prior lifestyle intervention attempts, and sometimes a failed trial of a lower-cost weight-loss option first. Medicare historically did not cover weight-loss drugs at all, but the GLP-1 Bridge Program starting July 2026 adds Wegovy coverage for eligible beneficiaries.
This is why many patients start on Ozempic (covered) for weight loss rather than Wegovy (the approved weight-loss version). The tradeoff is meaningful: Ozempic at its max dose typically produces 5 to 10% weight loss, while Wegovy at 2.4 mg produces closer to 15%.
Who Should Pick Wegovy vs Ozempic
Pick Wegovy if
- You have obesity (BMI 30+) or overweight (27+) with a weight-related condition, and your primary goal is weight loss
- You have cardiovascular disease plus obesity, even without T2D (SELECT trial indication)
- You have MASH / NAFLD with moderate to advanced fibrosis
- You are an adolescent age 12+ with obesity (Wegovy has pediatric approval, Ozempic does not)
- You want the maximum weight-loss effect within the semaglutide family
- You can get insurance coverage or afford the NovoCare cash program
Pick Ozempic if
- You have type 2 diabetes (the primary FDA indication)
- You have T2D plus established cardiovascular disease (Ozempic's CV indication)
- You have T2D plus chronic kidney disease (Ozempic's unique kidney protection indication)
- Your insurance covers Ozempic but not Wegovy, and some weight loss is still a reasonable secondary goal
- You want multi-dose pen convenience over single-dose pens
Can You Switch Between Wegovy and Ozempic?
Yes, and it's common.
Because they are the same molecule, switching is straightforward. Physicians typically match the new-drug dose to the old-drug dose when transitioning. If you were on Ozempic 1.0 mg weekly, your prescriber would usually start Wegovy at 1.0 mg or 1.7 mg (Wegovy does not have a 1.0 mg dose, so the next step is 1.7 mg). Allow 1 week between the last dose of the old drug and the first dose of the new one.
The reasons to switch vary. Most common: starting on Ozempic (easier insurance approval) and switching to Wegovy once the T2D diagnosis is on file or once weight-loss goals push past what Ozempic alone can deliver. Less common: switching from Wegovy to Ozempic due to side effects at the 2.4 mg dose. Both directions are clinically valid.